Sciele completes Alliant buy for $12.5M less than original price
Sciele Pharma has completed its acquisition of fellow USA-based Alliant Pharmaceuticals. Sciele will pay approximately $109.7 million in cash for Alliant, which includes around $14.0 million in indebtedness. The final purchase price is $12.5 million less than that originally negotiated due to the termination of the Lindane marketing deal between Alliant and Morton Grove Pharmaceuticals.
The terms of the Alliant purchase also include potential payments of up to $62.5 million dependent on certain profit and development targets for Alliant products. This is $7.5 million more than the previously announced $55.0 million.
Revises full-year outlook
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze